Skip to main content
SpringerLink
Log in

Clinical Role of Protein Binding of Quinolones

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Protein binding of antibacterials in plasma and tissues has long been considered a component of their pharmacokinetic parameters, playing a potential role in distribution, excretion and therapeutic effectiveness. Since the beginning of the ‘antibacterial era’, this factor has been extensively analysed for all antibacterial classes, showing that wide variations of the degree of protein binding occur even in the same antibacterial class, as with β-lactams. As the understanding of protein binding grew, the complexity of the binding system was increasingly perceived and its dynamic character described.

Studies of protein binding of the fluoroquinolones have shown that the great majority of these drugs exhibit low protein binding, ranging from approximately 20 to 40% in plasma, and that they are bound predominantly to albumin. The potential role in pharmacokinetics-pharmacodynamics of binding of fluoroquinolones to plasma, tissue and intracellular proteins has been analysed, but it has not been established that protein binding has any significant direct or indirect impact on therapeutic effectiveness. Regarding the factors influencing the tissue distribution of antibacterials, physicochemical characteristics and the small molecular size of fluoroquinolones permit a rapid penetration into extravascular sites and intracellularly, with a rapid equilibrium being established between intravascular and extravascular compartments. The high concentrations of these drugs achieved in tissues, body fluids and intracellularly, in addition to their wide antibacterial spectrum, mean that fluoroquinolones have therapeutic effectiveness in a large variety of infections.

The tolerability of quinolones has generally been reported as good, based upon long experience in using pefloxacin, ciprofloxacin and ofloxacin in clinical practice. Among more recently developed molecules, good tolerability has been reported for levofloxacin, moxifloxacin and gatifloxacin, but certain other new compounds have been removed from the market because of renal, hepatic and cardiac toxicity. To what extent the protein binding of fluoroquinolones can play a role in their tolerability is unclear. In terms of drug-drug interactions, the role of protein binding is questionable: several drug combinations can be responsible for toxicity, such as with β-lactams, metronidazole, theophylline, nonsteroidal anti-inflammatory agents or a series of drugs used for cardiac diseases, but protein binding does not seem to be involved in these interactions.

In conclusion, protein binding of fluoroquinolones appears to be a complex phenomenon, but has no clear role in therapeutic effectiveness or toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Craig WA, Byungse S. Theory and practical impact of binding of antimicrobials to serum proteins and tissue. Scand J Infect Dis 1978; Suppl. 14: 92–9

    CAS  Google Scholar 

  2. Peterson L, Gerding D. Influence of protein binding of antibiotics in serum pharmacokinetics and extra-vascular penetration: clinically useful concepts. Rev Infect Dis 1980; 2: 340–8

    Article  PubMed  CAS  Google Scholar 

  3. Evans WE, Schentag JJ, Jusko W. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics Inc., 1992

    Google Scholar 

  4. Hamilton-Miller JMT. Binding of antibiotics by non-albumin proteins. J Antimicrob Chemother 1984; 13: 303–14

    Article  PubMed  CAS  Google Scholar 

  5. Singlas E. Pharmacocinétique systémique des antibiotiques. In: Bergogne-Bérézin E, Brogard JM, editors. Bases biologiques de l’antibiothérapie. Paris: Masson Publishers (Collection des Abrégés), 1999

    Google Scholar 

  6. Goldstein A. The interaction of drugs and plasma proteins. Pharmacol Rev 1949; 1: 102–4

    Google Scholar 

  7. Curry SH. Binding to plasma protein. In: Curry SH, editor. Drug disposition and pharmacokinetics with a consideration of pharmacological and clinical relationships. 3rd ed. Oxford: Blackwell Scientific Publications, 1980

    Google Scholar 

  8. Brion N, Contrepois A, Carbon C. De la pharmacocinétiqur sérique à la pharmacocinétique extra-vasculaire des antibiotiques. Press Med 1983; 14: 6773–7

    Google Scholar 

  9. Tillement JP, Lhoste F, Giudicelli JF. Diseases and drug protein binding. Clin Pharmacol 1978; 3: 144–54

    Article  CAS  Google Scholar 

  10. Brogden RN, Ward A. Ceftriaxone: a reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once daily administration. Drugs 1988; 35: 604–45

    Article  PubMed  CAS  Google Scholar 

  11. Wise R. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet 1986; 11: 470–82

    Article  PubMed  CAS  Google Scholar 

  12. Kunin C, Craig WA, Kornguth M, et al. Influence of protein binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci 1973; 226: 214–24

    Article  PubMed  CAS  Google Scholar 

  13. Barza M. Principles of tissue penetration of antibiotics. J Antimicrob Chemother 1981; 3: 45–65

    Google Scholar 

  14. Vaudaux P. Peripheral inactivation of gentamicin. J Antimicrob Chemother 1981; 8 Suppl. A: 17–25

    Article  PubMed  CAS  Google Scholar 

  15. Thys JP, Husson M, Klastersky J. Inactivation of netilmicin and amikacin by intact or disrupted leucocytes. J Antimicrob Chemother 1984; 14: 435–8

    Article  PubMed  CAS  Google Scholar 

  16. Hooper WD, Wlfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985; 27: 375–9

    Article  Google Scholar 

  17. Jangknegt R. Fluorinated quinolones: areview of theirmode of action, antimicrobial activity, pharmacokinetics and clinical efficacy. Pharm Weekb Sci 1986; 8: 1–21

    Article  Google Scholar 

  18. Paton JH, Reeves DS. Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use. Drugs 1988; 36; 193–228

    Article  PubMed  CAS  Google Scholar 

  19. Wise R. Antimicrobial pharmacokinetic: expected concentrations in blood and urine. In Reeves DS, Wise R, Andrews JM, et al., editors. Clinical antimicrobial assays. Oxford: Oxford University Press, 1999: 27–33

    Google Scholar 

  20. Dalhoff A. A review of quinolone tissue pharmacokinetics. In: Fernandes PG, editor. International Telesymposium on Quinolones. Barcelona: J.R. Prous Science Publishers, 1989: 277–312

    Google Scholar 

  21. Wise R, Lister D, McNulty CA, et al. The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother 1986; 18 Suppl. D: 71–81

    PubMed  CAS  Google Scholar 

  22. Wolfson JS, Hooper DC. Fluoroquinolones antimicrobial agents. Clin Microbiol Rev 1989; 2: 378–424

    PubMed  CAS  Google Scholar 

  23. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992; 36: 1176–80

    Article  PubMed  CAS  Google Scholar 

  24. Decré D, Bergogne-Bérézin E. Pharmacokinetics of quinolones with special reference to the respiratory tree. J Antimicrob Chemother 1993; 31: 331–43

    Article  PubMed  Google Scholar 

  25. Boerema JBJ, Dalhoff A, Debruyne FMY. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. Chemotherapy 1985; 31: 13–8

    Article  PubMed  CAS  Google Scholar 

  26. Naber KG. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis 1989; 11 Suppl. 5: 1321–37

    Article  Google Scholar 

  27. Fong IW, Ledbetter WH, Vandenbroucke AC, et al. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother 1986; 29: 405–8

    Article  PubMed  CAS  Google Scholar 

  28. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996; 23 Suppl.: S19–S24

    Article  PubMed  CAS  Google Scholar 

  29. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58 Suppl. 2: 29–36

    Article  PubMed  CAS  Google Scholar 

  30. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997; 39 Suppl. B: 1–14

    Article  PubMed  CAS  Google Scholar 

  31. Forrest A, Chodosh S, Amentea A, et al. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 Suppl. A: 45–7

    Article  PubMed  CAS  Google Scholar 

  32. Liu W, Liu QF, Perkins R, et al. Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials. Antimicrob Agents Chemother 1998; 42: 1417–23

    PubMed  CAS  Google Scholar 

  33. Wise R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 1999; 17: 365–87

    Article  CAS  Google Scholar 

  34. Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998; 77 Suppl. 6: 7–11

    PubMed  CAS  Google Scholar 

  35. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. JAMA 1998; 279: 125–9

    Article  PubMed  CAS  Google Scholar 

  36. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101–19

    Article  PubMed  CAS  Google Scholar 

  37. O’Doherty B, Dutchman DA, Pettit R, et al. Randomized, double blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community acquired pneumonia. J Antimicrob Chemother 1997; 40 Suppl. A: 73–81

    Article  PubMed  Google Scholar 

  38. Carbon C. Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage. Eur J Clin Microb Infect Dis 1990; 9: 510–6

    Article  CAS  Google Scholar 

  39. Lorenz J, Martinot JB, Pfruender D. A double blind multicenter study of short course once daily trovafloxacin versus cefuroxime in the treatment of acute bacterial exacerbations of chronic bronchitis [abstract no. M175]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

  40. Deabate CA, Mcivor RA, Di Bartolo C, et al. Gatifloxacin, 400mgqd vs cefuroxime axetil 250mg bid in the treatment of acute exacerbations of chronic bronchitis [abstract no. M177]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

  41. Deabate CA, Russell MR, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute exacerbation of chronic bronchitis. Respir Care 1997; 42: 206–13

    Google Scholar 

  42. Deabate CA, Bagby BA, Ward JS, et al. A multicenter study of grepafloxacin 5 days 600 mg od, vs grepafloxacin 10 days 400 mg od, vs clarithromycin 14 days 500 mg bd in the treatment of acute bacterial maxillary sinusitis [abstract no. M167]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

  43. Burke T, Villanueva C, Mariano H, et al. Moxifloxacin versus cefuroxime axetil in the treatment of acute sinusitis [abstract no. M170]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco

  44. File TM, Segreti J, Dunbar L, et al. Multicentre, randomized study comparing the efficacy and safety of intravenous and peroral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965–72

    PubMed  CAS  Google Scholar 

  45. Carbon C, Ariza H, Rabies W, et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mild to moderate community-acquired pneumonia. Clin Microb Infect 1999; 5: 724–32

    Article  CAS  Google Scholar 

  46. Patel T, Pearl J, Williams J, et al. Efficacy and safety of 10 day moxifloxacin 400 mg once daily in the treatment of patients with community acquired pneumonia. Respir Med 2000; 94: 97–105

    Article  PubMed  CAS  Google Scholar 

  47. Tulkens PM. Intracellular pharmacokinetics and localization of antibiotics as predictors of their efficacy against intraphgocytic infections. Scand J Infect Dis 1991; Suppl. 74: 209–17

    Google Scholar 

  48. Rohwedder R. Ciprofloxacin in clinical practice: new light on established and emerging use. In: Lode H, editor. Stuttgart: Schwer-Verlag Publishers, 1990: 34–45

    Google Scholar 

  49. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992; 36: 1176–80

    Article  PubMed  CAS  Google Scholar 

  50. Dournon E, Mayaud C, Wolff M, et al. Comparison of the activity of three antibiotic regimens in severe legionnaires’ disease. J Antimicrob Chemother 1990; 26 Suppl. B: 129–39

    Article  PubMed  Google Scholar 

  51. Leysen DC, Haemers A, Pattyn SR. Mycobacteria and the new quinolones. Antimicrob Agents Chemother 1989; 33: 1–5

    Article  PubMed  CAS  Google Scholar 

  52. Wilcox M. A question of toxicity: antimicrobial development —the Libran approach. Antibiot Chemother 1999; 3: 9–16

    Google Scholar 

  53. Domagala JM. Structure activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685–706

    Article  PubMed  CAS  Google Scholar 

  54. Hooper DC. Structure of grepafloxacin relative to activity and safety profile. Clin Microb Infect 1998; 4 Suppl. 1: S15–S20

    Article  CAS  Google Scholar 

  55. Schentag JJ, Goss F. Quinolone pharmacokinetics in the elderly. Am J Med 1992; 92 Suppl. 4A: 33S–7S

    Article  PubMed  CAS  Google Scholar 

  56. Richer M, LeBel M. Pharmacokinetics of fluoroquinolones in selected populations. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents. 2nd ed. Washington, DC: American Society for Microbiology, 1993: 225–44

    Google Scholar 

  57. Rolfe MW, Schnapf BM. Management of the adult patient with cystic fibrosis. Clin Pulm Med 1995; 2: 75–87

    Article  Google Scholar 

  58. Nix DE. Drug-drug interactions with fluoroquinolone antimicrobial agents. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents. 2nd ed. Washington, DC: American Society for Microbiology, 1993: 245–58

    Google Scholar 

  59. Halliwell RF, Davey PG, Lambert JJ. The effects of quinolones and NSAIDS upon GABA-evoked currents recorded from rat dorsal root ganglion neurons. J Antimicrob Chemother 1991; 27: 209–18

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We are very grateful to Aventis Medical Team who have provided us with useful documentation and updated publications on fluoroquinolones.

Author information

Authors and Affiliations

  1. Bichat-Claude Bernard Medical School, University Paris 7, Paris, France

    Eugénie Bergogne-Bérézin

Authors
  1. Eugénie Bergogne-Bérézin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eugénie Bergogne-Bérézin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bergogne-Bérézin, E. Clinical Role of Protein Binding of Quinolones. Clin Pharmacokinet 41, 741–750 (2002). https://doi.org/10.2165/00003088-200241100-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200241100-00004

Keywords

Search

Navigation